GlassScriptPhysician profile
George S Howard
NPI 1144372004
$9,114.43
in general payments reported to CMS, 2019-2025
66 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $549 · 2021: $933 · 2022: $1,589 · 2023: $2,531 · 2024: $587 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159 · Education: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.40 |
| Education | $432.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,069.96 | 2019-2023 | Nplate, Xgeva, Blincyto |
| Genentech USA, INC. | $689.53 | 2019-2025 | Polivy, Tecentriq, Venclexta |
| Genzyme Corporation | $502.44 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $328.50 | 2022-2025 | Calquence, Lynparza, Imfinzi |
| Daiichi Sankyo INC. | $317.49 | 2022-2025 | Vanflyta, Enhertu, Injectafer |
| Gilead Sciences, INC. | $313.89 | 2019-2025 | Trodelvy |
| Pfizer INC. | $305.27 | 2019-2025 | |
| Janssen Biotech, INC. | $302.86 | 2020-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $279.25 | 2020-2025 | |
| Exelixis INC. | $278.69 | 2019-2025 | Cabometyx |
| Seagen INC. | $252.01 | 2020-2023 | Tukysa, Padcev |
| Astellas Pharma US INC | $235.71 | 2022-2023 | Xtandi, Xospata, Padcev |
| Abbvie INC. | $224.70 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $207.45 | 2021-2025 | |
| Celgene Corporation | $197.07 | 2019-2025 | Reblozyl, Pomalyst |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $186.58 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $180.37 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $169.18 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Kite Pharma, INC. | $167.42 | 2021-2025 | Yescarta |
| Sobi, INC | $164.74 | 2022-2025 | |
| Eisai INC. | $156.19 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.22 | 2019-2025 | |
| G1 Therapeutics, INC. | $150.82 | 2022 | |
| Incyte Corporation | $141.28 | 2020-2025 | Jakafi, Niktimvo |
| Lilly USA, LLC | $128.11 | 2021-2025 | Verzenio, Jaypirca |
| Beigene USA, INC. | $127.00 | 2022-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $116.93 | 2022-2025 | Fruzaqla, Ninlaro, Iclusig |
| Adaptive Biotechnologies Corporation | $115.04 | 2022-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Servier Pharmaceuticals LLC | $90.08 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $87.29 | 2021-2023 | Onivyde, Somatuline Depot |
| Mirati Therapeutics, INC. | $83.89 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $77.67 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $75.93 | 2020-2025 | Opdualag |
| Emd Serono, INC. | $75.67 | 2019-2023 | Bavencio, Tepmetko |
| Array Biopharma INC | $75.37 | 2023-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacosmos Therapeutics INC. | $66.78 | 2023-2025 | Monoferric |
| Blueprint Medicines Corporation | $58.66 | 2023-2025 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $56.64 | 2021-2025 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $54.60 | 2022-2023 | Imbruvica, Epkinly |
| Recordati_rare_diseases_inc. | $53.85 | 2022-2025 | Enjaymo |
| Tersera Therapeutics LLC | $44.50 | 2022 | |
| Karyopharm Therapeutics INC. | $44.08 | 2023-2025 | Xpovio |
| Stemline Therapeutics INC. | $43.20 | 2023 | Orserdu |
| Azurity Pharmaceuticals, INC. | $40.88 | 2025 | Danziten |
| Beone Medicines USA, INC. | $39.66 | 2025 | Tevimbra |
| Sumitomo Pharma America, INC. | $38.77 | 2023 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $38.49 | 2021-2025 | Qinlock |
| Regeneron Healthcare Solutions, INC. | $37.67 | 2025 | Libtayo |
| Octapharma USA, INC. | $37.40 | 2020-2025 | Octagam Immune Globulin (Human) |
| Alnylam Pharmaceuticals INC. | $33.28 | 2022-2023 | Givlaari |
| Sun Pharmaceutical Industries INC. | $28.21 | 2025 | |
| Boston Scientific Corporation | $26.90 | 2024 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Pharmaessentia USA Corporation | $24.56 | 2023 | Besremi |
| Eusa Pharma (US) LLC | $23.92 | 2022 | |
| Kyowa Kirin, INC. | $23.00 | 2025 | |
| Myovant Sciences INC. | $21.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.13 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.38 | 2023 | Xarelto |
| Tolmar, INC. | $16.77 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $16.77 | 2025 | Rubraca |
| Immunomedics, INC. | $16.53 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.50 | 2022 | |
| Spectrum Pharmaceuticals INC. | $15.09 | 2023 | Rolvedon |
| Morphosys, US INC. | $14.91 | 2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $14.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.